This, combined with previous pre-clinical data which showed enhancement of checkpoint blockade responses in pathway mutants, suggests that tumours with mutations in the IFNγ pathway are as efficiently controlled by the immune system as tumours that are sensitive to IFNγ. Here, IFNG is linked to neoplasm.